Inhibition of CYP2E1 leads to decreased advanced glycated end product formation in high glucose treated ADH and CYP2E1 over-expressing VL-17A cells
Abstract
Background In recent years, there has been a growing interest to explore the association between liver injury and diabetes. Advanced glycated end product (AGE) formation which characterizes diabetic complications is formed through hyperglycemia mediated oxidative stress and is itself a source for ROS. Further, in VL-17A cells over-expressing ADH and CYP2E1, greatly increased oxidative stress and decreased viability have been observed with high glucose exposure.Methods In VL-17A cells treated with high glucose and pretreated with the different inhibitors of ADH and CYP2E1, the changes in cell viability, oxidative stress parameters and formation of AGE, were studied.Results Inhibition of CYP2E1 with 10μM diallyl sulfide most effectively led to decreases in the oxidative stress and toxicity as compared with ADH inhibition with 2mM pyrazole or the combined inhibition of ADH and CYP2E1 with 5mM 4-methyl pyrazole. AGE formation was decreased in VL-17A cells when compared with HepG2 cells devoid of the enzymes. Further, AGE formation was decreased to the greatest extent with the inhibitor for CYP2E1 suggesting that high glucose inducible CYP2E1 and the consequent ROS aid AGE formation.Conclusions Thus, CYP2E1 plays a pivotal role in the high glucose induced oxidative stress and toxicity in liver cells as observed through direct evidences obtained utilizing the different inhibitors for ADH and CYP2E1.General significance The study demonstrates the role of CYP2E1 mediated oxidative stress in aggravating hyperglycemic insult and suggests that CYP2E1 may be a vital component of hyperglycemia mediated oxidative injury in liver.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CYP2E1 contributes to the production of AA and MAA adducts, as demonstrated in experimental rodent and cell culture models.
“In particular, CYP2E1 contributes to the production of AA and MAA adducts, as demonstrated in experimental rodent and cell culture models137,180,216,273.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [273]
Cites
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · see citing works
Role of Oxidative Stress in Development of Complications in Diabetes
Baynes, J. (1991) · Diabetes · doi:10.2337/diab.40.4.405 · Cited by 3,791 · see citing works
Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y., Pinsky, D. J., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,305 · see citing works
Mofrad, P., Contos, M., Haque, M., Sargeant, C. C., Fisher, R., Luketic, V., Sterling, R., Shiffman, M., Stravitz, R., & Sanyal, A. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,221 · see citing works
Molecular Understanding of Hyperglycemia's Adverse Effects for Diabetic Complications
Sheetz, M. J. (2002) · JAMA · doi:10.1001/jama.288.20.2579 · Cited by 1,003 · see citing works
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900 · see citing works
Advanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806 · see citing works
Nonenzymatic Browning in Vivo: Possible Process for Aging of Long-Lived Proteins
Monnier, V. M., & Cerami, A. (1981) · Science · doi:10.1126/science.6779377 · Cited by 768 · see citing works
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 716 · see citing works
The AGE‐receptor in the pathogenesis of diabetic complications
Vlassara, H. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.233 · Cited by 301 · see citing works
A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes
Santana, R. B., Xu, L., Babakhanlou‐Chase, H., Amar, S., Graves, D. T., & Trackman, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1502 · Cited by 251 · see citing works
Araki, N., Ueno, N., Chakrabarti, B., et al. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50004-7 · Cited by 250 · see citing works
Glucosylation of human collagen in aging and diabetes mellitus.
Schnider, S. L., & Kohn, R. R. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109950 · Cited by 212 · see citing works
Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus.
Vlassara, H., Brownlee, M., & Cerami, A. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.8.5190 · Cited by 201 · see citing works
Ethanol Cytotoxicity to a Transfected HepG2 Cell Line Expressing Human Cytochrome P4502E1
Wu, D., & Cederbaum, A. I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23914 · Cited by 194 · see citing works
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
Cusi, K. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283293015 · Cited by 185 · see citing works
Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression
Woodcroft, K. J., Hafner, M. S., & NOVAK, R. F. (2002) · Hepatology · doi:10.1053/jhep.2002.30691 · Cited by 164 · see citing works
Advanced glycation end products and diabetic complications: A General overview
Peppa, Μ., & Vlassara, H. (2005) · HORMONES · doi:10.14310/horm.2002.11140 · Cited by 153 · see citing works
Glycation as the glucose link to diabetic complications.
Gugliucci, A. (2000) · PubMed · Cited by 127 · see citing works
Donohue, T. M., Osna, N. A., & Clemens, D. L. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.010 · Cited by 124 · see citing works
Self-citationCytochrome P450 2E1‐dependent oxidant stress and upregulation of anti‐oxidant defense in liver cells
Cederbaum, A. I. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04595.x · Cited by 118 · see citing works
Baba, S. P., Barski, O. A., Ahmed, Y., O’Toole, T. E., Conklin, D. J., Bhatnagar, A., & Srivastava, S. (2009) · Diabetes · doi:10.2337/db09-0375 · Cited by 117 · see citing works
Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study
Trombetta, M., Spiazzi, G., Zoppini, G., & Muggeo, M. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02590.x · Cited by 115 · see citing works
The role of advanced glycation end products in the development of atherosclerosis
Peppa, Μ., Uribarri, J., & Vlassara, H. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0008-6 · Cited by 112 · see citing works
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells
Iwamoto, K., Kanno, K., Hyogo, H., Yamagishi, S., Takeuchi, M., Tazuma, S., & Chayama, K. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-007-2152-7 · Cited by 110 · see citing works
Posttranslational Modification of Human Glyoxalase 1 Indicates Redox-Dependent Regulation
Birkenmeier, G., Stegemann, C., Hoffmann, R., Günther, R., Huse, K., & Birkemeyer, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010399 · Cited by 95 · see citing works
Relationship between acetaldehyde levels and cell survival in ethanol-metabolizing hepatoma cells
Clemens, D. L., Forman, A., Jerrells, T. R., Sorrell, M. F., & Tuma, D. J. (2002) · Hepatology · doi:10.1053/jhep.2002.32668 · Cited by 82 · see citing works
Self-citationFatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?
Lonardo, A. (1999) · Digestive Diseases · doi:10.1159/000016909 · Cited by 80 · see citing works
MOLECULAR ENZYMOLOGY OF THE GLYOXALASE SYSTEM
Mannervik, B. (2008) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2008.23.1-2.13 · Cited by 74 · see citing works
Acute ethanol exposure inhibits insulin signaling in the liver
He, J., de la Monte, S. M., & Wands, J. R. (2007) · Hepatology · doi:10.1002/hep.21904 · Cited by 71 · see citing works
Characterization of Cytochrome P4502E1 Turnover in Transfected HepG2 Cells Expressing Human CYP2E1
Yang, M., & Cederbaum, A. I. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1997.9907 · Cited by 66 · see citing works
Ethanol Metabolism Alters Interferon Gamma Signaling in Recombinant HepG2 Cells *
Osna, N. A., Clemens, D. L., & Donohue, T. M. (2005) · Hepatology · doi:10.1002/hep.20909 · Cited by 51 · see citing works
Self-citationProteasome Activation by Hepatitis C Core Protein Is Reversed by Ethanol-Induced Oxidative Stress
Osna, N. A., White, R. L., Krutik, V. M., Wang, T., Weinman, S. A., & Donohue, T. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.063 · Cited by 50 · see citing works
Induction of cytochrome promotes liver injury in ob/ob mice
Dey, A., & Cederbaum, A. I. (2007) · Hepatology · doi:10.1002/hep.21603 · Cited by 46 · see citing works
Self-citationAdvanced Glycoxidation: A New Risk Factor for Cardiovascular Disease?
Peppa, Μ., Uribarri, J., & Vlassara, H. (2002) · Cardiovascular Toxicology · doi:10.1385/ct:2:4:275 · Cited by 38 · see citing works
Dey, A., Kessova, I. G., & Cederbaum, A. I. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.01.013 · Cited by 36 · see citing works
Self-citationMcVicker, B. L., Tuma, P. L., Kharbanda, K. K., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2609 · Cited by 35 · see citing works
Geldanamycin, an Inhibitor of Hsp90, Potentiates Cytochrome P4502E1-Mediated Toxicity in HepG2 Cells
Dey, A., & Cederbaum, A. I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101808 · Cited by 32 · see citing works
Self-citationHandl, M., Filová, E., Kubala, M. E., Lánský, Z., Koláčná, L., Vorlíček, J., Trč, T., & Amler, E. (2007) · Physiological Research · doi:10.33549/physiolres.930934 · Cited by 32 · see citing works
Miyamoto, A., Takeshita, M., Pan-Hou, H. S. K., & Fujimori, H. (2008) · The Journal of Toxicological Sciences · doi:10.2131/jts.33.209 · Cited by 19 · see citing works
Chandrasekaran, K., Swaminathan, K., Kumar, S. M., Clemens, D. L., & Dey, A. (2012) · Integrative Biology · doi:10.1039/c2ib00155a · Cited by 18 · see citing works
Self-citationGlycation of aspartate aminotransferase by methylglyoxal, effect of hydroxycitric and uric acid
Boušová, I., Bacílková, E., Dobrijević, S., & Dršata, J. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0161-y · Cited by 8 · see citing works
Kornbrust, D. J., & Dietz, D. (1985) · Chemico-Biological Interactions · doi:10.1016/0009-2797(85)90037-7 · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M., & Song, B.-J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00561-7 · Cited by 411 · see citing works
- Authors
- Swaminathan, K., Kumar, S. M., Clemens, D. L., & Dey, A.
- Affiliations
- Anna University, Chennai (IN)
- VA Nebraska Western Iowa Health Care System (US)
- Corresponding author
- Dey, Aparajita
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 1830
- Issue
- 10
- Pages
- 4407-4416
- ISSN
- 0304-4165 (ISSN-L)
- OpenAlex
- W1997367330
- Cited by
- 21
- References
- 43
- Citations by year
- 2025: 1 · 2023: 2 · 2021: 4 · 2020: 3 · 2019: 3 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 3
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochimica et Biophysica Acta (BBA) - General Subjects (publishedVersion)
- PubMed (publishedVersion)
- Funders
- KBC Research Foundation, Chennai
- Department of Science and Technology (Fast Track Scheme For Young Scientists)
- Department of Biotechnology (Rapid Grant For Young Investigators)
- Veterans Administration
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- CYP2E1, advanced glycation end products, aldehyde dehydrogenase, high glucose, oxidative stress, reactive oxygen species, diallyl sulfide, 4-methylpyrazole, pyrazole derivatives, liver injury, diabetes mellitus, hyperglycemia, hepatocyte cytotoxicity
- MeSH terms
- Alcohol Dehydrogenase, Allyl Compounds, Cell Line, Glucose, Humans, Pyrazoles, Sulfides, Glycation End Products, Advanced, Reactive Oxygen Species, Oxidative Stress, Cytochrome P-450 CYP2E1, Cytochrome P-450 CYP2E1 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review